Andere Sprachen Protagonist Therapeutics, Inc.

Aktien

A2AP32

US74366E1029

PTGX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 30.04.2024			% 5 Tage	% 1. Jan.
25.11 ^USD	-1.76%		-6.48%	+9.51%

03.04.	Insider von Protagonist Therapeutics verkaufte Aktien im Wert von $707.750, laut einer aktuellen SEC Einreichung	MT
26.03.	Protagonist Therapeutics, Inc. gibt Update zur Verify-Patientenrekrutierung und zum Zeitpunkt der Veröffentlichung von Top-Line-Daten	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	03.04.
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data	27.03.
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	26.03.
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda	18.03.
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study	11.03.
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis	11.03.
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing	04.03.
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing	04.03.
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing	04.03.
Protagonist Therapeutics: Q4 Earnings Snapshot	27.02.
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.02.
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda	01.02.
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset	31.01.
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024	30.01.
Protagonist Therapeutics Insider Sold Shares Worth $1,506,000, According to a Recent SEC Filing	15.12.
Protagonist Therapeutics Earns $10 Million Milestone Payment in Ulcerative Colitis Trial	13.12.
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	13.12.
Protagonist Therapeutics, Inc. Announces $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis	13.12.
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib	28.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Protagonist Therapeutics, Inc.

Aktien

A2AP32

US74366E1029

PTGX

Andere Sprachen

Filter